SCHEMBL4314405

SCHEMBL4314405

COc1c(OCCCl)ccc(/C=C/c2n[nH]c3ccccc23)c1N

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 7/20 0.37
KDR P35968 5/20 0.36
KDM4E B2RXH2 5/20 0.34
ALDH1A1 P00352 3/20 0.34
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
FGFR1 P11362 2/20 0.33
MAPT P10636 1/20 0.33
GAA P10253 2/20 0.33
PDPK1 O15530 1/20 0.33
CYP3A4 P08684 1/20 0.33
CDK4 P11802 2/20 0.33
CCNA2 P20248 2/20 0.33
CCND1 P24385 2/20 0.33
CDK2 P24941 2/20 0.33
CCND3 P30281 2/20 0.33
NPC1 O15118 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4314415 1.00 CHEK1 (0.37) CHEK1KDRKDM4EALDH1A1CTNNB1
SCHEMBL4322028 0.96 CHEK1 (0.37) CHEK1KDRKDM4EALDH1A1CTNNB1
SCHEMBL4322021 0.96 CHEK1 (0.37) CHEK1KDRKDM4EALDH1A1CTNNB1
SCHEMBL27691448 0.92 CHEK1 (0.37) CHEK1KDRKDM4EALDH1A1CTNNB1
SCHEMBL4311665 0.86 DRD2 (0.35) CHEK1KDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4311662 0.86 DRD2 (0.35) CHEK1KDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4315506 0.81 MEN1 (0.45) CHEK1KDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4315513 0.81 MEN1 (0.45) CHEK1KDRKDM4EALDH1A1SMN1; SMN2
SCHEMBL4308261 0.80 MAPT (0.41) CHEK1KDM4EALDH1A1CTNNB1WNT3A
SCHEMBL4308256 0.80 MAPT (0.41) CHEK1KDM4EALDH1A1CTNNB1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101111483-B IGF-1R inhibitors KYOWA HAKKO KIRIN CO.,LTD. (JP) 2011-12-14 CN disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
CN-101111483-A IGF-1R inhibitors KYOWA HAKKO KOGYO KK (JP) 2008-01-23 CN disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 CHEK1 3274/4885KDR 75/4885KDM4E 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.